论文部分内容阅读
自体外周血干细胞(PBPC)移植是近年来肿瘤治疗研究的热点之一。局限期小细胞肺癌(LD-SCLC)的不良预后,启发人们探讨PBPC移植对其疗效。 经组织病理学确诊的LD-SCLC患者,先接受 2周期 VIP-E方案[足叶乙甙(VP16)500mg/m~2、异环磷酰胺(IFO)4g/m~2、顺铂(DDP)50mg/m~2、表阿霉素(EPI)50mg/m~2]的诱导化疗。在第2周期化疗用药结束后24小时,开始每天予G-CSF 5μg/kg皮下注射,进行PBPC的动员扩增。PBPC采集的时机根据外周血白细胞计数以及CD34+细胞在白细胞中所占比例决定,多在化疗
Transplantation of autologous peripheral blood stem cells (PBPCs) has been one of the hot topics in the research of tumor therapy in recent years. The poor prognosis of limited-stage small cell lung cancer (LD-SCLC) has inspired people to explore the efficacy of PBPC transplantation. Patients with LD-SCLC diagnosed by histopathology undergo two cycles of VIP-E regimen [500 mg/m2 of VP16, ifosfamide (IFO) 4 g/m~2, cisplatin (DDP) 50mg/m2, epirubicin (EPI) 50mg/m~2 induction chemotherapy. Twenty-four hours after the end of the second cycle of chemotherapeutic administration, G-CSF was subcutaneously injected at 5 μg/kg every day to perform mobilization expansion of PBPC. The timing of PBPC acquisition is determined by the peripheral blood leukocyte count and the proportion of CD34+ cells in leukocytes, mostly in chemotherapy.